Enovis (NYSE:ENOV) Reaches New 52-Week Low - Here's What Happened

Key Points

• Enovis shares fell to a new 52-week low of $18.50, last trading at $18.70 versus a prior close of $19.03. The stock’s market capitalization is approximately $1.08 billion.
• Analysts have recently reduced several price targets, though sentiment remains positive overall: 10 analysts rate the stock a Buy, with a consensus “Moderate Buy” rating and an average target of $40.38.
• Enovis exceeded quarterly earnings expectations, reporting $0.90 in EPS versus an $0.85 estimate and $582.78 million in revenue. Company insiders purchased roughly 24,293 shares worth $470,519 over the past 90 days.

Enovis Corporation (NYSE:ENOV - Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $18.50 and last traded at $18.70, with a volume of 127204 shares changing hands. The stock had previously closed at $19.03.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ENOV shares. Wells Fargo & Company lowered their target price on shares of Enovis from $39.00 to $33.00 and set an "overweight" rating on the stock in a report on Wednesday, September 2nd. BTIG Research dropped their price objective on shares of Enovis from $40.00 to $36.00 and set a "buy" rating for the company in a report on Tuesday, September 1st. Citizens Jmp cut their price objective on Enovis from $55.00 to $47.00 and set a "market outperform" rating for the company in a research report on Wednesday, September 2nd. UBS Group reaffirmed a "buy" rating and issued a $51.00 target price (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Finally, BMO Capital Markets set a $27.00 price objective on Enovis in a report on Tuesday, September 1st. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Enovis has a consensus rating of "Moderate Buy" and a consensus price target of $40.38.

Enovis Price Performance

The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $1.08 billion, a PE ratio of -0.97 and a beta of 1.31. The stock's 50-day moving average is $25.40 and its two-hundred day moving average is $24.16.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same quarter in the previous year, the business earned $0.79 earnings per share. The company's revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts predict that Enovis Corporation will post 3.15 EPS for the current year.

Insiders Place Their Bets

In other Enovis news, CEO Damien Mcdonald acquired 13,035 shares of the business's stock in a transaction on Friday, September 4th. The shares were bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the transaction, the chief executive officer directly owned 247,077 shares of the company's stock, valued at $4,731,524.55. The trade was a 5.57% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, insider Oliver Engert bought 5,140 shares of Enovis stock in a transaction on Thursday, September 3rd. The stock was acquired at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the purchase, the insider owned 61,238 shares of the company's stock, valued at approximately $1,191,691.48. This trade represents a 9.16% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders have purchased 24,293 shares of company stock valued at $470,519. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP bought a new stake in shares of Enovis during the third quarter valued at approximately $83,435,000. Paradigm Capital Management Inc. NY purchased a new stake in shares of Enovis in the second quarter valued at approximately $28,533,000. California State Teachers Retirement System grew its stake in Enovis by 1,635.6% in the second quarter. California State Teachers Retirement System now owns 1,335,833 shares of the company's stock worth $27,652,000 after purchasing an additional 1,258,867 shares in the last quarter. Bank of America Corp DE bought a new position in Enovis in the second quarter worth approximately $11,502,000. Finally, AQR Capital Management LLC increased its holdings in Enovis by 682.6% during the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company's stock worth $15,627,000 after purchasing an additional 434,646 shares during the period. Hedge funds and other institutional investors own 98.45% of the company's stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.